Chemical Component Summary

Namevincristine
FormulaC46 H56 N4 O10
Molecular Weight824.958
TypeNON-POLYMER
Isomeric SMILESCC[C@@]1(C[C@H]2C[C@@](c3c(c4ccccc4[nH]3)CCN(C2)C1)(c5cc6c(cc5OC)N([C@@H]7[C@]68CCN9[C@H]8[C@@](C=CC9)([C@H]([C@@]7(C(=O)OC)O)OC(=O)C)CC)C=O)C(=O)OC)O
InChIInChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
InChIKeyOGWKCGZFUXNPDA-CFWMRBGOSA-N

Chemical Details

Formal Charge0
Atom Count116
Chiral Atom Count9
Bond Count124
Aromatic Bond Count16

Drug Info: DrugBank

DrugBank IDDB00541 
NameVincristine
Groups
  • investigational
  • approved
DescriptionVincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).
Synonyms
  • Vincristine sulfate
  • Vincristinum
  • 22-Oxovincaleukoblastin
  • Vincristin
  • Leurocristine
Brand Names
  • Vincasar PFS
  • Vincristine Sulfate Injection
  • Vincristine Sulfate Inj 5mg/vial USP
  • VinCRIStine Sulfate
  • Vincristine Sulfate Inj 1mg/ml USP
IndicationTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
Categories
  • Agents Causing Muscle Toxicity
  • Alkaloids
  • Antimitotic Agents
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
ATC-CodeL01CA02
CAS number57-22-7

Drug Targets

NameTarget SequencePharmacological ActionActions
Tubulin beta chainMREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGTYHGDSDLQLDRISVY...unknowninhibitor
Tubulin alpha-4A chainMRECISVHVGQAGVQMGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFT...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Cytochrome P450 3A7MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNA...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 5388993
ChEMBL CHEMBL499458